Page last updated: 2024-08-16

ribavirin and didanosine

ribavirin has been researched along with didanosine in 45 studies

Research

Studies (45)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	17 (37.78)	18.2507
2000's	19 (42.22)	29.6817
2010's	8 (17.78)	24.3611
2020's	1 (2.22)	2.80

Authors

Authors	Studies
Andrei, G; Balzarini, J; Blache, Y; Chapat, JP; Chavignon, O; De Clercq, E; Debouzy, JC; Elhakmaoui, A; Essassi, EM; Gueiffier, A; Kerbal, A; Lhassani, M; Snoeck, R; Teulade, JC; Witvrouw, M	1
Alam, N; Hong, J; Im, KS; Jung, JH; Lee, CK; Li, F; Liu, Y; Wang, W	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Chun, MW; Jeong, LS; Kim, KR; Moon, HR; Park, AY	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chizhov, AO; Geisman, AN; Khandazhinskaya, AL; Kochetkov, SN; Naesens, L; Novikov, MS; Ozerov, AA; Pannecouque, C; Seley-Radtke, KL; Valuev-Elliston, VT	1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Caliò, R; Perno, CF	1
Balzarini, J; De Clercq, E; Lee, CK; Schols, D	1
Ahluwalia, GS; Broder, S; Cooney, DA; Fridland, A; Hartman, NR; Johns, DG; Kageyama, S; Mitsuya, H	1
De Clercq, E	1
Crumpacker, C; Finberg, RW; Heagy, W; Lopez, PA	1
Balzarini, J; De Clercq, E; Herdewijn, P; Lee, CK	1
Balzarini, J; De Clercq, E; Naesens, L; Robins, MJ	1
Ahluwalia, GS; Cooney, DA; Driscoll, JS; Johns, DG; Mitsuya, H; Shirasaka, T	1
Morris, DJ	1
Balzarini, J; Bernhardt, A; Mamont, P; Weibel, M	1
Brun-Vezinet, F; Pépin, JM; Simon, F	1
Ahluwalia, GS; Cooney, DA; Driscoll, JS; Johns, DG; Mitsuya, H	1
Allen, LB; Brazier, AD; Hollingshead, MG; Prichard, MN; Quenelle, DC; Shannon, WM; Taylor, BA; Westbrook, L	1
Baba, M; Fujiwara, M; Ijichi, K; Konno, K; Machida, H; Mori, K; Morozumi, M; Shigeta, S; Yokota, T	1
Bassiakos, Y; Booth, D; Clax, PA; Connor, JD; Cooney, E; Crumpacker, CS; Erice, A; Griffith, BP; Holden-Wiltse, J; Hussey, S; Japour, AJ; Johanneson, N; Lertora, JJ; McLaren, C; Meehan, PM; Pollard, R; Timpone, J; Walesky, M; Wood, K	1
Beauchamp, D; Bergeron, MG; Désormeaux, A; Dusserre, N; Gourde, P; Harvie, P; Lansac, N; Omar, RF; Simard, M; Tremblay, M	1
Brinkman, K; Kakuda, TN	1
Abad, S; Chauvelot-Moachon, L; Salmon-Céron, D; Silbermann, B; Sogni, P	1
Perronne, C	1
Brenner, B; Campeol, N; Klein, MB; Lalonde, RG; Wainberg, MA	1
Butt, AA	1
Gerber, JG; Glesby, MJ	1
Bruno, R; Filice, G; Sacchi, P	1
Antela, A; Bárcena, R; Casado, JL; Dronda, F; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Navas, E; Perez-Elías, MJ; Quereda, C	1
Boxwell, D; Fleischer, R; Sherman, KE	1
Ballesteros, AL; Clotet, B; Côté, H; Fuster, D; Garrabou, G; López, S; Martínez, E; Miró, O; Planas, R; Rey-Joly, C; Salas, A; Tor, J; Tural, C; Videla, S	1
Margot, NA; Miller, MD	1

Reviews

6 review(s) available for ribavirin and didanosine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[New therapeutic trends in AIDS]. La Clinica terapeutica, 1992, Volume: 140, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Deoxyadenosines; Didanosine; Dideoxynucleosides; Humans; Poly I-C; Poly U; Randomized Controlled Trials as Topic; Ribavirin; RNA, Double-Stranded; Zalcitabine; Zidovudine	1992
Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug safety, 1994, Volume: 10, Issue:4 Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine	1994
[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?]. Pathologie-biologie, 1993, Volume: 41, Issue:8 Pt 2 Topics: Acyclovir; Didanosine; Drug Synergism; Drug Therapy, Combination; Female; Foscarnet; HIV-1; Humans; In Vitro Techniques; Male; Ribavirin; Zalcitabine; Zidovudine	1993
[Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications]. Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Didanosine; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Life Style; Mitochondria; Monitoring, Physiologic; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Viral Load; Zidovudine	2002
Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity. The AIDS reader, 2003, Volume: 13, Issue:7 Topics: Acidosis, Lactic; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Synergism; Hepatitis C; HIV Infections; Humans; Metabolic Clearance Rate; Pancreatitis; Ribavirin	2003

Trials

2 trial(s) available for ribavirin and didanosine

Article	Year
A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1996, Nov-01, Volume: 13, Issue:3 Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; Genetic Variation; Giant Cells; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Viremia	1996
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both. Antiviral therapy, 2004, Volume: 9, Issue:6 Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors	2004

Article

Year

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1996, Nov-01, Volume: 13, Issue:3

Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; Genetic Variation; Giant Cells; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Viremia

1996

Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.

Antiviral therapy, 2004, Volume: 9, Issue:6

Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors

2004

Other Studies

37 other study(ies) available for ribavirin and didanosine

Article	Year
Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents. Journal of medicinal chemistry, 1996, Jul-05, Volume: 39, Issue:14 Topics: Animals; Antiviral Agents; Chlorocebus aethiops; HeLa Cells; Humans; Nucleosides; Pyridines; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured; Vero Cells	1996
New saponins from the starfish Certonardoa semiregularis. Journal of natural products, 2002, Volume: 65, Issue:11 Topics: Animals; Antineoplastic Agents; Antiviral Agents; Artemia; HeLa Cells; Humans; Korea; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Saponins; Starfish; Stereoisomerism; Steroids	2002
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Design, synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives. Bioorganic & medicinal chemistry, 2007, Jan-01, Volume: 15, Issue:1 Topics: Antiviral Agents; Drug Design; Encephalomyocarditis virus; Herpesvirus 1, Human; Herpesvirus 2, Human; HIV-1; HIV-2; Imides; Microbial Sensitivity Tests; Molecular Conformation; Perylene; Stereoisomerism; Vesicular stomatitis Indiana virus	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2 Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus. Bioorganic & medicinal chemistry, 2016, 06-01, Volume: 24, Issue:11 Topics: Animals; Antiviral Agents; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; HIV-1; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Uracil	2016
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16 Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone	2016
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2',3'-dideoxyinosine on human immunodeficiency virus in peripheral blood lymph Biochemical and biophysical research communications, 1991, Jul-31, Volume: 178, Issue:2 Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Synergism; Guanosine Diphosphate; Guanosine Monophosphate; Guanosine Triphosphate; HIV-1; Humans; Inosine Monophosphate; Kinetics; Lymphocytes; Ribavirin; Ribonucleosides	1991
Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Molecular pharmacology, 1991, Volume: 40, Issue:1 Topics: Antiviral Agents; Cells, Cultured; Chromatography; Didanosine; Dideoxyadenosine; Drug Synergism; HIV; Humans; IMP Dehydrogenase; Inosine; Inosine Monophosphate; Nucleotides; Phosphorylation; Ribavirin; Stimulation, Chemical	1991
Ribavirin for HIV. Lancet (London, England), 1991, Aug-17, Volume: 338, Issue:8764 Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Ribavirin	1991
Inhibition of immune functions by antiviral drugs. The Journal of clinical investigation, 1991, Volume: 87, Issue:6 Topics: Acyclovir; Antiviral Agents; Cell Cycle; Cells, Cultured; Concanavalin A; Didanosine; DNA; Ganciclovir; Humans; Immunity; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Proteins; Ribavirin; Zidovudine	1991
Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus. The Journal of biological chemistry, 1991, Nov-15, Volume: 266, Issue:32 Topics: Biotransformation; Cell Line; Didanosine; Drug Synergism; Giant Cells; Guanine Nucleotides; HIV-1; Humans; Hypoxanthine; Hypoxanthines; Inosine Monophosphate; Kinetics; Models, Biological; Ribavirin	1991
Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside. Journal of acquired immune deficiency syndromes, 1990, Volume: 3, Issue:12 Topics: Animals; Antiviral Agents; Cell Line; Cell Transformation, Viral; Cytopathogenic Effect, Viral; Didanosine; Dideoxyadenosine; Drug Synergism; Fibroblasts; HIV; Humans; Mice; Mice, Inbred Strains; Moloney murine sarcoma virus; Ribavirin; Sarcoma, Experimental; Virus Replication	1990
Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine. Molecular pharmacology, 1994, Volume: 46, Issue:5 Topics: Adenosine Deaminase Inhibitors; Cell Line; Didanosine; Dideoxyadenosine; Drug Synergism; HIV; IMP Dehydrogenase; Pentostatin; Phosphorylation; Ribavirin	1994
Potentiating effect of (2-[2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl]-phenyl]ethenyl) -phosphonic acid (MDL 74,428), a potent inhibitor of purine nucleoside phosphorylase, on the antiretroviral activities of 2',3'-dideoxyinosine combined with rib Biochemical pharmacology, 1994, Jul-19, Volume: 48, Issue:2 Topics: 3T3 Cells; Animals; Antiviral Agents; Cell Transformation, Viral; Cytopathogenic Effect, Viral; Didanosine; Drug Interactions; HIV-1; Humans; Male; Mice; Moloney murine sarcoma virus; Organophosphorus Compounds; Pentosyltransferases; Purines; Ribavirin; Tumor Cells, Cultured	1994
Enhanced stimulation by ribavirin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of purine 2'-beta-fluoro-2',3'-dideoxynucleosides. Molecular pharmacology, 1993, Volume: 44, Issue:3 Topics: Didanosine; Dideoxyadenosine; Dideoxynucleosides; Drug Synergism; HIV-1; Phosphorylation; Purine Nucleosides; Ribavirin; Structure-Activity Relationship	1993
In vitro and in vivo enhancement of ddI activity against Rauscher murine leukemia virus by ribavirin. Antiviral research, 1995, Volume: 27, Issue:3 Topics: Animals; Cell Line; Didanosine; Drug Synergism; Leukemia, Experimental; Male; Mice; Rauscher Virus; Retroviridae Infections; Ribavirin; Tumor Virus Infections; Weight Gain	1995
Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral research, 1996, Volume: 31, Issue:1-2 Topics: Anti-HIV Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; HIV-1; Humans; Ribavirin; Uracil; Zidovudine	1996
Ribavirin potentiates the efficacy and toxicity of 2',3'- dideoxyinosine in the murine acquired immunodeficiency syndrome model. The Journal of pharmacology and experimental therapeutics, 1996, Volume: 279, Issue:2 Topics: Animals; Antiviral Agents; CD4-CD8 Ratio; Didanosine; Drug Synergism; Drug Therapy, Combination; Female; Immunoglobulin M; Lymphatic Diseases; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Ribavirin; Splenomegaly	1996
Mitochondrial toxic effects and ribavirin. Lancet (London, England), 2001, Jun-02, Volume: 357, Issue:9270 Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Interactions; HIV Seropositivity; HIV-1; Humans; Ribavirin	2001
Mitochondrial toxic effects and ribavirin. Lancet (London, England), 2001, Jun-02, Volume: 357, Issue:9270 Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; Drug Interactions; Hepatitis C; HIV Seropositivity; HIV-1; Humans; Middle Aged; Mitochondria; Pancreatitis; Ribavirin	2001
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS (London, England), 2003, May-02, Volume: 17, Issue:7 Topics: Anti-HIV Agents; Cells, Cultured; Didanosine; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Interferon-alpha; Ribavirin; Virus Replication	2003
New warning for ddI. AIDS patient care and STDs, 2002, Volume: 16, Issue:12 Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; Drug Interactions; Drug Labeling; Hepatitis C; HIV Infections; Humans; Ribavirin	2002
Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. The AIDS reader, 2003, Volume: 13, Issue:7 Topics: Acidosis, Lactic; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Synergism; Drug Therapy, Combination; Fatal Outcome; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancreatitis; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load	2003
Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo. AIDS (London, England), 2003, Dec-05, Volume: 17, Issue:18 Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; Drug Synergism; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-gamma; Ribavirin	2003
High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antiviral therapy, 2004, Volume: 9, Issue:1 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Didanosine; Female; Hepatitis C; HIV Infections; Humans; Incidence; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Proportional Hazards Models; Ribavirin	2004
Nucleoside analogues and mitochondrial toxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-15, Volume: 38, Issue:8 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Mitochondria; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine	2004
In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antiviral therapy, 2005, Volume: 10, Issue:2 Topics: Adenine; Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Synergism; HIV-1; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir	2005
Hepatitis C and didanosine: risk of lactic acidosis. Prescrire international, 2005, Volume: 14, Issue:80 Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Comorbidity; Contraindications; Didanosine; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin	2005